Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis (COBBANA)
Primary Purpose
Peripheral Vascular Diseases, Hemostasis
Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Lyostypt® AND Surgicel®
Lyostypt®
Surgicel®
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Vascular Diseases focused on measuring PTFE Graft, Suture Hole Bleeding, Hemostasis
Eligibility Criteria
Inclusion Criteria:
- Patients with an indication for a peripheral vascular reconstruction due to peripheral vascular disease (PVD) including femoro-femoral, femoro-popliteal and femoro-crural reconstructions or the need of a crossover including femoro-femoral or ilaco-femoro reconstruction.
- suture hole bleeding of peripheral arterial bypass anastomosis using PTFE graft prosthesis
- Written informed consent
Exclusion Criteria:
- Emergency surgery
- Patients with coagulopathy or uremia
- Reoperation within one month at the same location
- Pregnant and Breastfeeding Women
- Known or suspected allergies or hypersensitivity to any of the used devices (e.g. to material of bovine origin)
- Severe comorbidity (ASA ≥ 4)
- Life expectancy less than 12 months
- Current immunosuppressive therapy (more than 40 mg of corticoid per day or ezathioprin)
- Chemotherapy within last 4 weeks
- Radiotherapy on the treated region within the last 2 months
- Severe psychiatric or neurologic diseases
- Lack of compliance
Sites / Locations
- Klinikum Hanau GmbH, Gefaesschirurgie
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
1
2
3
4
Arm Description
distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
distal and proximal Anastomosis Lyostypt®
distal and proximal Anastomosis Surgicel®
Outcomes
Primary Outcome Measures
Time to hemostasis
Secondary Outcome Measures
Number of Complications
Postoperative Mortality
Efficacy Rating of Study Device evaluated by Surgeon
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00837954
Brief Title
Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis
Acronym
COBBANA
Official Title
Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
April 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aesculap AG
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this trial is to demonstrate that the bleeding time of suture holes after construction of arterial bypass anastomosis is shorter after treatment with Lyostypt® than with Surgicel®
Detailed Description
Hemostasis in peripheral vascular surgery is made more difficult by the need for direct arterial and arterial graft suturing as well as by systemic anticoagulation to prevent thrombosis during periods of vascular occlusion. Polytetrafluorethylene (PTFE) is one of the most frequently used graft materials for vascular replacement or bypass in the case when no autologous venae are available (1). However, the insufficient elasticity of PTFE and its porosity promote the development of suture hole bleeding (2,3) which can cause considerable loss of blood and prolongation of operations (2).
This study is designed to demonstrate the superiority of Lyostypt® to oxidized cellulose (Surgicel®) for hemostasis of suture hole bleeding in arterial bypass anastomoses after vascular reconstruction. Lyostypt® is an absorbable, wet stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII. Therefore collagen is very effective in hemostasis. Collagen is cell-friendly whereas other hemostats significantly disturb cell growth. Advantages of collagen fleece are fast induction of hemostasis, low tissue reaction and fast absorption (15). Furthermore, collagen was shown to be the best overall hemostatic agent in microvascular surgery. Authors concluded that collagen fleece establish faster hemostasis than oxidized cellulose and that it was resorbed faster than oxidized cellulose (15).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Vascular Diseases, Hemostasis
Keywords
PTFE Graft, Suture Hole Bleeding, Hemostasis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
Arm Title
2
Arm Type
Active Comparator
Arm Description
distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
Arm Title
3
Arm Type
Active Comparator
Arm Description
distal and proximal Anastomosis Lyostypt®
Arm Title
4
Arm Type
Active Comparator
Arm Description
distal and proximal Anastomosis Surgicel®
Intervention Type
Device
Intervention Name(s)
Lyostypt® AND Surgicel®
Other Intervention Name(s)
Lyostypt®, Surgicel®
Intervention Description
The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.
Intervention Type
Device
Intervention Name(s)
Lyostypt®
Intervention Description
The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.
Intervention Type
Procedure
Intervention Name(s)
Surgicel®
Intervention Description
The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.
Primary Outcome Measure Information:
Title
Time to hemostasis
Time Frame
Minutes
Secondary Outcome Measure Information:
Title
Number of Complications
Time Frame
30 days after surgery
Title
Postoperative Mortality
Time Frame
30 days after surgery
Title
Efficacy Rating of Study Device evaluated by Surgeon
Time Frame
intraoperatively
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with an indication for a peripheral vascular reconstruction due to peripheral vascular disease (PVD) including femoro-femoral, femoro-popliteal and femoro-crural reconstructions or the need of a crossover including femoro-femoral or ilaco-femoro reconstruction.
suture hole bleeding of peripheral arterial bypass anastomosis using PTFE graft prosthesis
Written informed consent
Exclusion Criteria:
Emergency surgery
Patients with coagulopathy or uremia
Reoperation within one month at the same location
Pregnant and Breastfeeding Women
Known or suspected allergies or hypersensitivity to any of the used devices (e.g. to material of bovine origin)
Severe comorbidity (ASA ≥ 4)
Life expectancy less than 12 months
Current immunosuppressive therapy (more than 40 mg of corticoid per day or ezathioprin)
Chemotherapy within last 4 weeks
Radiotherapy on the treated region within the last 2 months
Severe psychiatric or neurologic diseases
Lack of compliance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hardy Schumacher, Prof. Dr.
Organizational Affiliation
Klinikum Hanau GmbH
Official's Role
Study Chair
Facility Information:
Facility Name
Klinikum Hanau GmbH, Gefaesschirurgie
City
Hanau
State/Province
Hessen
ZIP/Postal Code
63450
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
8731143
Citation
Bellon JM, Bujan J, Contreras LA, Hernando A, Jurado F. Similarity in behavior of polytetrafluoroethylene (ePTFE) prostheses implanted into different interfaces. J Biomed Mater Res. 1996 May;31(1):1-9. doi: 10.1002/(SICI)1097-4636(199605)31:13.0.CO;2-S.
Results Reference
background
PubMed Identifier
2974302
Citation
Carney WI Jr, Lilly MP. Intraoperative evaluation of PTFE, Dacron and autogenous vein as carotid patch materials. Ann Vasc Surg. 1987 Dec;1(5):583-6. doi: 10.1016/S0890-5096(06)61445-3.
Results Reference
background
PubMed Identifier
8859403
Citation
Zdrahala RJ. Small caliber vascular grafts. Part I: state of the art. J Biomater Appl. 1996 Apr;10(4):309-29. doi: 10.1177/088532829601000402.
Results Reference
background
PubMed Identifier
17020801
Citation
Lumsden AB, Heyman ER; Closure Medical Surgical Sealant Study Group. Prospective randomized study evaluating an absorbable cyanoacrylate for use in vascular reconstructions. J Vasc Surg. 2006 Nov;44(5):1002-1009; discussion 1009. doi: 10.1016/j.jvs.2006.06.039. Epub 2006 Oct 3.
Results Reference
background
PubMed Identifier
3810486
Citation
Miller CM, Sangiolo P, Jacobson JH 2nd. Reduced anastomotic bleeding using new sutures with a needle-suture diameter ratio of one. Surgery. 1987 Feb;101(2):156-60.
Results Reference
background
PubMed Identifier
3999241
Citation
Citrin P, Doscher W, Wise L, Margolis IB. Control of needle hole bleeding with ethyl-cyanoacrylate glue (Krazy Glue). J Vasc Surg. 1985 May;2(3):488-90. doi: 10.1067/mva.1985.avs0020488.
Results Reference
background
PubMed Identifier
4570330
Citation
Hait MR, Robb CA, Baxter CR, Borgmann AR, Tippett LO. Comparative evaluation of Avitene microcrystalline collagen hemostat in experimental animal wounds. Am J Surg. 1973 Mar;125(3):284-7. doi: 10.1016/0002-9610(73)90042-1. No abstract available.
Results Reference
background
PubMed Identifier
3520941
Citation
Hatsuoka M, Seiki M, Sasaki K, Kashii A. Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis. Thromb Res. 1986 May 1;42(3):407-12. doi: 10.1016/0049-3848(86)90269-0. No abstract available.
Results Reference
background
PubMed Identifier
7401211
Citation
Silverstein ME, Keown K, Owen JA, Chvapil M. Collagen fibers as a fleece hemostatic agent. J Trauma. 1980 Aug;20(8):688-94. doi: 10.1097/00005373-198008000-00010.
Results Reference
background
PubMed Identifier
11052282
Citation
Czerny M, Verrel F, Weber H, Muller N, Kircheis L, Lang W, Steckmeier B, Trubel W. Collagen patch coated with fibrin glue components. Treatment of suture hole bleedings in vascular reconstruction. J Cardiovasc Surg (Torino). 2000 Aug;41(4):553-7.
Results Reference
background
PubMed Identifier
15079782
Citation
Joseph T, Adeosun A, Paes T, Bahal V. Randomised controlled trial to evaluate the efficacy of TachoComb H patches in controlling PTFE suture-hole bleeding. Eur J Vasc Endovasc Surg. 2004 May;27(5):549-52. doi: 10.1016/j.ejvs.2004.01.018.
Results Reference
background
PubMed Identifier
10477639
Citation
Jackson MR, Gillespie DL, Longenecker EG, Goff JM, Fiala LA, O'Donnell SD, Gomperts ED, Navalta LA, Hestlow T, Alving BM. Hemostatic efficacy of fibrin sealant (human) on expanded poly-tetrafluoroethylene carotid patch angioplasty: a randomized clinical trial. J Vasc Surg. 1999 Sep;30(3):461-6. doi: 10.1016/s0741-5214(99)70073-x.
Results Reference
background
PubMed Identifier
14560228
Citation
Taylor LM Jr, Mueller-Velten G, Koslow A, Hunter G, Naslund T, Kline R; Beriplast B Investigators. Prospective randomized multicenter trial of fibrin sealant versus thrombin-soaked gelatin sponge for suture- or needle-hole bleeding from polytetrafluoroethylene femoral artery grafts. J Vasc Surg. 2003 Oct;38(4):766-71. doi: 10.1016/s0741-5214(03)00474-9.
Results Reference
background
PubMed Identifier
11888460
Citation
Glickman M, Gheissari A, Money S, Martin J, Ballard JL; CoSeal Multicenter Vascular Surgery Study Group. A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly than gelfoam/thrombin: results of a randomized controlled trial. Arch Surg. 2002 Mar;137(3):326-31; discussion 332. doi: 10.1001/archsurg.137.3.326.
Results Reference
background
PubMed Identifier
15221572
Citation
Schonauer C, Tessitore E, Barbagallo G, Albanese V, Moraci A. The use of local agents: bone wax, gelatin, collagen, oxidized cellulose. Eur Spine J. 2004 Oct;13 Suppl 1(Suppl 1):S89-96. doi: 10.1007/s00586-004-0727-z. Epub 2004 Jun 22.
Results Reference
background
PubMed Identifier
8866036
Citation
Wachol-Drewek Z, Pfeiffer M, Scholl E. Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin. Biomaterials. 1996 Sep;17(17):1733-8. doi: 10.1016/0142-9612(96)87654-x.
Results Reference
background
Citation
Uranüs, S. ; Pfeifer, J. ; Alimoglu, O. ; Özmen, T. Laparoskopische Eingriffe an der Milz Chir Gastroenterol 2004;20(Suppl.2):35-41 (DOI:10.1159/000083352)
Results Reference
background
PubMed Identifier
2625015
Citation
Heidemann D, Hartenstein B. [Effect of local hemostyptics on human gingiva fibroblasts in culture]. Dtsch Z Mund Kiefer Gesichtschir. 1989 May-Jun;13(3):226-9. German.
Results Reference
background
PubMed Identifier
4829453
Citation
Haussmann P, Mergard UE, Kohnlein HE. [Effect of various hemostatics. Animal experiment studies]. Fortschr Med. 1974 May 9;92(13):579-80. No abstract available. German.
Results Reference
background
PubMed Identifier
7786985
Citation
Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994 Dec;50(4):1029-41.
Results Reference
background
PubMed Identifier
17400486
Citation
Jensen LP, Lepantalo M, Fossdal JE, Roder OC, Jensen BS, Madsen MS, Grenager O, Fasting H, Myhre HO, Baekgaard N, Nielsen OM, Helgstrand U, Schroeder TV. Dacron or PTFE for above-knee femoropopliteal bypass. a multicenter randomised study. Eur J Vasc Endovasc Surg. 2007 Jul;34(1):44-9. doi: 10.1016/j.ejvs.2007.01.016. Epub 2007 Apr 2.
Results Reference
background
PubMed Identifier
14603216
Citation
Ballotta E, Renon L, Toffano M, Da Giau G. Prospective randomized study on bilateral above-knee femoropopliteal revascularization: Polytetrafluoroethylene graft versus reversed saphenous vein. J Vasc Surg. 2003 Nov;38(5):1051-5. doi: 10.1016/s0741-5214(03)00608-6.
Results Reference
background
PubMed Identifier
15557906
Citation
Devine C, McCollum C; North West Femoro-Popliteal Trial Participants. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg. 2004 Nov;40(5):924-31. doi: 10.1016/j.jvs.2004.08.033.
Results Reference
background
PubMed Identifier
16807001
Citation
Eiberg JP, Roder O, Stahl-Madsen M, Eldrup N, Qvarfordt P, Laursen A, Greve M, Florenes T, Nielsen OM, Seidelin C, Vestergaard-Andersen T, Schroeder TV. Fluoropolymer-coated dacron versus PTFE grafts for femorofemoral crossover bypass: randomised trial. Eur J Vasc Endovasc Surg. 2006 Oct;32(4):431-8. doi: 10.1016/j.ejvs.2006.04.018. Epub 2006 Jun 27.
Results Reference
background
PubMed Identifier
16617028
Citation
Kapfer X, Meichelboeck W, Groegler FM. Comparison of carbon-impregnated and standard ePTFE prostheses in extra-anatomical anterior tibial artery bypass: a prospective randomized multicenter study. Eur J Vasc Endovasc Surg. 2006 Aug;32(2):155-68. doi: 10.1016/j.ejvs.2005.12.015. Epub 2006 Apr 17.
Results Reference
background
PubMed Identifier
12514593
Citation
Klinkert P, Schepers A, Burger DH, van Bockel JH, Breslau PJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg. 2003 Jan;37(1):149-55. doi: 10.1067/mva.2002.86.
Results Reference
background
PubMed Identifier
23332688
Citation
Qerimi B, Baumann P, Husing J, Knaebel HP, Schumacher H. Collagen hemostat significantly reduces time to hemostasis compared with cellulose: COBBANA, a single-center, randomized trial. Am J Surg. 2013 Jun;205(6):636-41. doi: 10.1016/j.amjsurg.2012.05.033. Epub 2013 Jan 17.
Results Reference
result
PubMed Identifier
19788736
Citation
Baumann P, Schumacher H, Husing J, Luntz S, Knaebel HP. A randomized, controlled, prospective trial to evaluate the haemostatic effect of Lyostypt versus Surgicel in arterial bypass anastomosis: "COBBANA" trial. Trials. 2009 Sep 29;10:91. doi: 10.1186/1745-6215-10-91.
Results Reference
result
Learn more about this trial
Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis
We'll reach out to this number within 24 hrs